hydromorphone
You searched for “Dilaudid”. Shortages and recalls for every US product with this active ingredient.
Shortage
In shortageFDA shortage list as of Nov 20, 2026
Injection, 0.5 mg/0.5 mL NexJect™ Single-dose Syringe Luer Lock (no needle)
Not available1 product at this strength
- Hospira, Inc., a Pfizer Company (NDC 0409-4264-01)Limited AvailabilityLimited Supply Available. Next Delivery: November 2026; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay
Injection, 1 mg/1 mL
Not availableAll 4 products at this strength
- Fresenius Kabi USA, LLC (NDC 76045-009-06)UnavailableNext release November 2026. Check wholesalers for inventory.
- Hospira, Inc., a Pfizer Company (NDC 0409-1283-37)UnavailableNext Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay
- Fresenius Kabi USA, LLC (NDC 63323-852-25)UnavailableNext release November 2026. Check wholesalers for inventory.
- Fresenius Kabi USA, LLC (NDC 76045-009-11)UnavailableNext release January 2027. Check wholesalers for inventory.
Injection, 0.25 mg/ 0.5 mL NexJect™ Single-dose Syringe Luer Lock (no needle)
Not available1 product at this strength
- Hospira, Inc., a Pfizer Company (NDC 0409-1805-01)UnavailableNext Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay
Injection, 1 mg/1 mL Syringes
Not available1 product at this strength
- Hospira, Inc., a Pfizer Company (NDC 0409-1283-31)Limited AvailabilityLimited Supply Available. Next Delivery and Estimated Recovery: December 2026
Injection, 10 mg/1 mL
Some makers short- Fresenius Kabi USA, LLC (NDC 63323-851-10)
- Teva Pharmaceuticals USA, Inc. (NDC 0703-0018-01)
- Hospira, Inc., a Pfizer Company (NDC 0409-2634-01)
- Teva Pharmaceuticals USA, Inc. (NDC 0703-0110-03)
- Fresenius Kabi USA, LLC (NDC 63323-851-15)
All 7 products at this strength
- Fresenius Kabi USA, LLC (NDC 63323-851-10)AvailableCheck wholesalers for inventory
- Teva Pharmaceuticals USA, Inc. (NDC 0703-0113-03)Limited AvailabilityEstimated recovery: November 2026
- Teva Pharmaceuticals USA, Inc. (NDC 0703-0018-01)Available
- Hospira, Inc., a Pfizer Company (NDC 0409-2634-01)Available
- Teva Pharmaceuticals USA, Inc. (NDC 0703-0110-03)Available
- Fresenius Kabi USA, LLC (NDC 63323-851-15)AvailableCheck wholesaler for inventory
- Fresenius Kabi USA, LLC (NDC 63323-851-50)UnavailableNext release January 2027. Check wholesalers for inventory.
Injection, 2 mg/1 mL
Some makers short- Hikma Pharmaceuticals USA, Inc. (NDC 0641-0121-25)
- Hospira, Inc., a Pfizer Company (NDC 0409-3365-10)
All 6 products at this strength
- Fresenius Kabi USA, LLC (NDC 76045-010-11)UnavailableNext release not available at this time. Check wholesalers for inventory.
- Hikma Pharmaceuticals USA, Inc. (NDC 0641-0121-25)AvailableAdditional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released.
- Hikma Pharmaceuticals USA, Inc. (NDC 0641-6254-01)UnavailableProduct temporarily on backorder. Additional lots will be available in the November 2026 timeframe.
- Fresenius Kabi USA, LLC (NDC 63323-853-25)UnavailableNext release November 2026. Check wholesalers for inventory.
- Hospira, Inc., a Pfizer Company (NDC 0409-3365-10)Available
- Hospira, Inc., a Pfizer Company (NDC 0409-1312-36)Limited AvailabilityLimited Supply Available. Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay
Injection, 2 mg/1 mL Syringes
Available1 product at this strength
- Hospira, Inc., a Pfizer Company (NDC 0409-1312-30)Available
Injection, .2 mg/1 mL
Available1 product at this strength
- Fresenius Kabi USA, LLC (NDC 76045-121-11)AvailableCheck wholesalers for inventory
Injection, 4 mg/1 mL
Available1 product at this strength
- Fresenius Kabi USA, LLC (NDC 63323-854-10)AvailableCheck wholesalers for inventory
Injection, 500 mg/50 mL (10 mg/mL)
Available1 product at this strength
- Hospira, Inc., a Pfizer Company (NDC 0409-2634-50)Available
Injection, 50 mg/5 mL (10 mg/mL)
Available1 product at this strength
- Hospira, Inc., a Pfizer Company (NDC 0409-2634-05)Available
Injection, 4 mg/1 mL Syringes
Available1 product at this strength
- Hospira, Inc., a Pfizer Company (NDC 0409-1304-31)Available
Availability is what manufacturers report to the FDA, not what a particular pharmacy has in stock.
Recalls
3 active, 120 pastFDA recall data as of Nov 11, 2026
- Class IIHYDROmorphone HCl 10 mg in 0.9% Sodium Chloridge, 50 mL syringe (0.2 mg/mL), Rx Only, SSM Health Care Corporation Outsou
CGMP Deviations: Discontinuation of the Quality program by manufacturer that would assure product meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess.
- Class IIHydromorphone Hydrochloride Injection, USP, 50mg/5mL (10 mg/mL) packaged in a) 1 mL ampules, b) 5 mL ampules, c) 50 mL v
CGMP Deviations: Firm went out of business and could no longer continue stability studies.
- Class IIIHydromorphone HCL PF, 10mg/50 mL (0.2mg/mL) in NACL, Injection for IV use, 50 mL Syringe, STAQ Pharma Inc., 14135 E 42nd
Labeling: Incorrect or Missing Lot and/or Exp Date
A recall usually covers specific lots. Check the lot number on your pack and ask your pharmacist before changing anything.
Information from FDA public data (openFDA), which the FDA says may be unvalidated. Not medical advice.